SCHEDULE: Armistice Capital Cuts Processa Pharma Stake to 4.99%

Armistice Capital and Steven Boyd have reduced their beneficial ownership in Processa Pharmaceuticals, Inc. to 4.99% of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 1 to their Schedule 13G.
• The filing indicates their beneficial ownership in Processa Pharmaceuticals, Inc. (Issuer) is 2,644,376 shares of common stock.
• This amount represents 4.99% of the Issuer's common stock.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The Reporting Persons hold shared voting power and shared dispositive power over all 2,644,376 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor to below the 5% threshold, which can signal reduced confidence or a strategic exit from a larger position.

Positives

• NA

Negatives

• The reduction in beneficial ownership to below the 5% threshold by a significant institutional investor like Armistice Capital could be interpreted as a decrease in conviction or a strategic divestment.

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a standard disclosure for institutional investors like Armistice Capital, indicating changes in their passive ownership stake in publicly traded companies. Such amendments are common when an investor's holdings cross certain percentage thresholds, either above or below.

Stakeholder Impact

• Shareholders may interpret the reduction in Armistice Capital's stake as a potential signal of decreased confidence in the company's future prospects, which could influence their investment decisions.

Key Dates

Recommendation

While the filing itself is a routine disclosure of ownership, the reduction of a significant institutional stake to just below the 5% threshold could be viewed as a negative signal. However, without further context on the investor's strategy or the company's fundamentals, a 'hold' recommendation is appropriate, advising investors to monitor future developments and the company's performance closely.

Keywords

Processa Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, Pharmaceuticals